anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:An antitumor agent containing a specific glycerol derivative. CONSTITUTION:An antitumore agent effective against leukemia, solid cancer, etc., containing a compound shown by the formula I (R&lt;1&gt; is alkyl, or alkylcarbamoyl; R&lt;2&gt; and R&lt;3&gt; are H, lower alkyl, or R&lt;1&gt; and R&lt;2&gt; together with neighboring N form ring). It has low toxicity, and administered orally or parenterally to the whole body or the affected part. A dose is preferably 50 mg-2g/day and it is administered dividedly once-several times daily or by installation. The compound shown by the formula I is obtained by reacting a compound shown by the formula II (R&lt;4&gt; is protecting group) with a compound shown by the formula III (X is Cl, or Br), and eliminating the protecting group R&lt;4&gt;. This composition may contain other active components as long as no unfavorable mutual action is produced by blending with the compound shown by the formula I.
PURPOSE:A novel high polymer, obtained by bonding a formyl group-containing polysaccharide derivative to an amino group-containing physiologically active substance and a bifunctional ligand compound, and useful as a carrier for preparing a radioactive pharmaceutical having high specific radioactivity. CONSTITUTION:A compound is obtained by bonding 1 molcule polysaccharide derivative having 3 or more formly groups in the molecule except dialdehyde starch, e.g. amylose or amylopectin, to &gt;=2 molecules bifunctional ligand compound containing -NH2 and &gt;=1 molecule physiologically active substance containing -NH2, e.g. blood protein, enzyme or hormone, through -CH=N- or -CH2NH- bonds. Examples of the bifunctional ligand compound include compounds of the formula (R&lt;1&gt; and R&lt;2&gt; are H, 1-3C alkyl or phenyl). EFFECT:The aimed radioactive pharmaceutical is obtained by chelating the above- mentioned compound with a radioactive metal element without deteriorating or reducing the activity of the physiologically active substance.
Novel benzimidazoles of the formula &lt;FORM:1087345/C2/1&gt; wherein R1 represents a hydrogen atom or a C1- 5 alkyl, aralkyl or acyl radical, one of R5 and R6 represent a hydrogen or halogen atom or a C1- 5 alkyl, C1- 5 alkoxy, C1- 5 alkylthio, phenoxy, phenylthio, phenyl or halophenyl radical and the other represents hydrogen and n is 1 or 2, are prepared by reacting a substituted aniline and a substituted furan of the respective formulae &lt;FORM:1087345/C2/2&gt; wherein A represents hydrogen or a nitro group and B represents a carboxy, esterified carboxy or haloformyl radical, to form an amide of the formula &lt;FORM:1087345/C2/3&gt; when A is hydrogen, nitrating this amide to convert A to nitro, and reducing the nitro compound with hydrogen (under certain conditions and when n is 2, the reduction may cause the elimination of one chlorine atom); by reacting the required o-phenylene diamine with the required chloro-substituted-2-furfural, the process being effected in the presence of nitrobenzene benzene or being followed by reaction with an oxidizing agent on the intermediate Schiff type base formed; or by reacting an amidine of the formula &lt;FORM:1087345/C2/4&gt; wherein R5, R6 and n have the above significance (obtainable from the required aniline and required chloro substituted 2-cyano-furan), with a chlorinating or brominating agent to produce the corresponding N-haloamidine and treating this compound with a base.  Ethyl - 2,3,4,5 - tetrachloro - tetrahydrofuran - 2 - carboxylate is prepared by treating ethyl 2-furoate with chlorine, is converted into a mixture of ethyl mono- and poly-chloro-2-furoates by heating the mixture may be separated by fractionally distilling, saponifying the fraction boiling between 123 DEG  and 145 DEG  C. at 20 mm. pressure, forming the calcium salts of the resulting mixture of acids, filtering off the precipitated calcium salts and acidifying the filtrate to precipitate 3,5-dichloro-2-furoic acid or treating an aqueous solution of the said calcium salts with hydrochloric acid and extracting 4,5-dichloro-2-furoic acid.  4 - Chloro - 2 - furoic acid is prepared by the zinc dust-HCl treatment of the corresponding 4,5-dichloro-compound.  4 - Fluoro - 41 - aminobiphenyl is prepared by nitrating 4-fluoro-biphenyl and reducing the resulting 4-fluoro-41-nitrobiphenyl.  Pharmaceutical compositions having anthelmintic activity contain as the active ingredient a compound of the first formula above. The compositions may be in the form of capsules, tablets, boluses, drenches or solutions.
NEW MATERIAL:The compound of formulaI(R is 8-24C and R&#39; is 1-24C saturated or unsaturated straight or branched chain aliphatic hydrocarbon group). USE:Cosmetic. It has also pharmaceutical activities such as hematocyte-production promoting effect to the marrow, antiphlogistic activity, antitumor activity, etc. PROCESS:The compound of formulaIis prepared by (1) reacting the glycidyl ether of formula V with the protected glycerin of formula VI in the presence of a basic catalyst or an acidic catalyst at 90-120 deg.C, (2) etherifying the resultant compound of formula II with an etherifying agent (e.g. alkyl bromide) in the presence of an alkaline substance (e.g. NaOH) and preferably a catalytic amount of quaternary onium salt (preferably quaternary ammonium salt) to obtain the compound of formula IV, and (3) hydrolyzing the product by heating in water in the presence of 0.05-1.0N acid catalyst (e.g. sulfuric acid).
The inner boot includes a body portion (2) enclosing the skier&#39;s foot and a leg portion (3) extending from it. A cut-out delimited by a pair of flap extends longitudinally of the leg portion. The flaps overlap one another and are held closed by a length of pull-out band (10) connected at one end to one of the flaps. The band engages a ring-like member (11) fitted to the opposite flap. A rear flap (20) partly overlies the lower part of the cut-out to improve ankle security. The leg and body portions are moulded together as an integral unit.
PROBLEM TO BE SOLVED: To obtain the subject preparation effective for improving the moisture- retaining performance of the cuticle layer and exhibiting excellent chapped skin improving effect by using a specific partly new amide derivative as an active component and optionally adding a nonionic surfactant to the component. SOLUTION: This preparation contains about 0.1-20wt.% of an amide derivative of formula I [R&lt;1&gt; and R&lt;2&gt; are each a 1-40C hydrocarbon group which may have OH; X and Y are each O or methylene (X and Y are not O at the same time); Z is H or 2,3-dihydroxypropyl; (m) is 1-6; (n) is 0-3]. The system is preferably further incorporated with about 0.1-5wt.% of a surfactant (e.g. a glyceryl ether). The compound of formula II is a new compound among the compounds of formula I. The compound of formula I or the compound of formula III which is one of the compound of formula I can be produced e.g. from the amide derivative of formula IV via an amide derivative of formula V (R&lt;4&gt; is methoxymethyl, etc.). A compound wherein Z is 2,3-dihydroxypropyl can be produced from the compound of formula III via two steps.
2092996 9206068 PCTABS00011 Applicants describe the synthesis of tamoxifen derivatives, most particularly halo, halo alkyl and hydroxy tamoxifen derivatives, wherein with the native tamoxifen molecule includes a substituted chemical group positioned on the aliphatic chain of the tamoxifen molecule. Particular halogenated tamoxifen derivatives of the invention include chloro, bromo, iodo and fluoro tamoxifen derivatives, and corresponding lower alkyl halogenated forms. The halogenated tamoxifen derivatives possess superior binding affinities for estrogen receptor rich tissues, such as uterine tissue and breast tissue, relative to unsubstituted native tamoxifen. In particular, the fluoro and bromo tamoxifen derivatives have potential use in imaging estrogen receptors by PET whereas the iodinated tamoxifens have potential use in imaging estrogen receptors by SPECT. The bromomethyl tamoxifen derivatives are demonstrated to bind estrogen receptors with the greatest enhancement of binding affinity over native tamoxifen. Rapid and efficient methods of preparing the tamoxifen derivatives having high specific activity (&gt;6 ci/.mu.mol) are also disclosed. Aliphatic chain substituted tamoxifen derivatives are shown to possess greater estrogen receptor binding affinity and more potent tumor cell inhibition than tamoxifen or tamoxifen derivatives substituted at other locations on the molecule (i.e., non-aliphatic chain substituted tamoxifen). The tamoxifen derivatives of the present invention may advantageously be used as anticancer therapeutic agents to halt estrogen-receptor positive tumors, such as those of breast and uterine tissue.
Constituents are introduced into a receptacle (B) through which there slides a piston (A) connected at its lower part to at least one element (D) provided with a multi-channelled passage (C). By reciprocating the piston (A) in the receptacle (B), air or inert gas is entrapped into the liquid or liquid- solid mixture. Spring (E) assists in the reciprocation. The passage (C) diameter is preferably in the range 0.2 mm to 10 mm. The piston (A) may be guided and sealed against the receptacle (B) by an O ring (Fig. 2). &lt;IMAGE&gt;
But the oral liquid of special invention and release sweating and expelling toxin is called for short the sweating and expelling toxin oral liquid.Its composition and partition: 1.9 one-tenth of sucrose sugar, 0.4 one-tenth in Rhizoma Zingiberis Recens, 0.2 one-tenth of chilli, 0.2 one-tenth in Fructus Piperis, 0.5 one-tenth in Herba Alii fistulosi, 7 one-tenth of drinking waters, as the saying goes, general rule is not bitterly, and is bitterly then obstructed.Catching a cold mostly is because blood capillary stops up, and causes the headache fever, feeble.But this oral liquid is bacteriostasis and sterilization both, can force antiperspirant to urge antiperspirant again, and it is taken, and is very natural, makes the unimpeded and discharge toxin of blood capillary, so get well soon.Can regard special beverage at ordinary times.Long-term drink also has such benefit: 1. improve digestive system, people&#39;s appetite is heightened.2. eliminate by aching all over that rheumatism causes relaxation and happiness after the dysphoria at first.Sum up its advantage: 1. production process is simple.2. cost hangs down the profit height.3. effect is remarkable.4. taste peppery sweet matching.5. be free from side effects.6. not perishable.7, demand is big.Be suitable for numerous personages.8. but not only can cure the disease but also body-building, make the best of both worlds.To the significant of this project, should develop energetically, produce for a long time.
PURPOSE: A method for analyzing medical image data through the communication network and the recording media are provided so that a user can perform the diagnosis of illness precisely based on a secondary medical image data generated by the analysis of a digitalized primary medical image data, transmitted through the communication network, by analytic programs contained in a server. CONSTITUTION: Analytic programs to analyze medical images, a user database to manage members and a file database to store computer files are configured in a server(S110). Users accesses the server using their terminals(S120). If a user is an authenticated member, the server shows him a list of programs and receives the user&#39;s input to select the programs(S130). If the user clicks a start button, a primary medical image data stored in his terminal is transmitted to the server through the communication network(S140). The server analyzes the primary medical image data and generates a secondary image data(S150). The server transmits the generated primary medical image data to the user&#39;s terminal(S160).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an endoluminal stent and a stent graft including a graft.  &lt;P&gt;SOLUTION: This invention provides the stent graft. This releases an agent which induces the in vivo adhesion of the stent graft to vessel walls, or otherwise, induces or accelerates an in vivo fibrotic reaction which adheres this stent graft to the vessel wall. The method for producing such a stent graft and the use method are also provided. In a related aspect, the stent graft is constructed so that this graft itself is constituted of a material which induces adhesion to the vessel wall or fiber formation.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The present invention relates to a release liner which is suitable for a transdermal preparation and a method for manufacturing the same. The release liner which is suitable for a transdermal preparation of the present invention is attached to the adhesive-coating side of a medical patch for transdermal or mucosal absorption and expresses release performance. The release liner comprises: a polyethylene terephthalate film; and a silicone release coating layer on one side of the polyethylene terephthalate film, containing epoxy compounds and silane compounds. The film is characterized by satisfying formulas 1-3 (formula 1: 10 &amp;le; RF &amp;le; 50, formula 2: 100 &amp;le; CA &amp;le; 115, formula 3: TSi &amp;le; 8.0). The release liner has superior release ability and shows print pitch stability because silicone residues are transferred on the back side of the release liner at a remarkably low transfer rate. Therefore, the release liner functions in a medical patch, especially a transdermal patch. A large amount of the release liners with uniform physical properties is provided by an in-line coating method and a simultaneous biaxially stretching method.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a doctor with an image for a patient&#39;s local region, that of his/her normal region and that of his/her affected region, as references to the doctor&#39;s diagnosis.  &lt;P&gt;SOLUTION: A remote host apparatus 10 is installed in a medical institution via a network 20 such as a LAN, the Internet or a GPRS. The remote host apparatus 10 is connected to medical equipment 30 and a computer 40, which is arranged in a consultation room of each doctor, via the network 20. A plurality of reference images for the patient&#39;s local regions are stored in a reference image database 11. Digital images for the patient&#39;s local regions, which are obtained by using the medical equipment 30, and basic information on the patient are connected together and stored in a patient database 12. The reference image database 11 is searched, and the reference images closely akin in the patient&#39;s sex and age, the local regions of the body, etc. are searched out.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Coryza baccine was prepd. by cultivating Haemophilus Paragallinarum (HPG), which is the causing microbe of infectious coryza, in special liquid culture ground. Thus, HPG-inoculated vitellus was picked and mixed with 20% yeast extract, 10% bacto-dextrose and distilled water. The mixt. was freezed at&lt;-10≰C and dissolved in 38-40≰C water bath. The process was repeated 3 times. The dissolved mixt. was maintained at 3-5≰C cold and dark room for 5-7 days and filtrated to give growth accelerating agent for liquid culture ground.
The present invention relates to evaluating the progress of a managed care organization&#39;s (MCO) patient wellness goals using a segmented patient population and patient self-reported medical readings. In operation, a wellness area and goal are predefined, and the patient&#39;s self-reported medical readings relate to the wellness area and goal. The patient population can be subdivided with a patient population segmentation rule creating a patient population recordset. An analysis is then performed on the patient population recordset to determine a ‘percentage of goal’ based on patient medical readings when compared to the predefined wellness goal. The ‘percentage of goal’ can be determined for the managed care organization as well as for individual patients, and individual healthcare facilities that are assigned to the managed care organization. Wellness areas that goals can be set for include hypertension, diabetes, body weight, body mass index, cholesterol, and other wellness areas.
PURPOSE:To obtain the titled soft capsule containing Lactobacillus bifidus in a state survivable stably for a long period without emitting ill odor, by adding a protective agent to the powder of the bifidus bacteria, suspending in a hardened oil having narrow melting point range to obtain the core liquid for capsule, and encapsulating the core liquid with a gelatin skin. CONSTITUTION:Bifidus bacteria are added with a protective agent (preferably dried starch), and suspended in a hardened oil having a melting point of 30-45 deg.C and melting point range of &lt;=3 deg.C (e.g. coconut oil, palm kernel oil, etc.), and the obtained core oil is encapsulated with a gelatin skin to obtain the titled soft capsule. The solid content of the gelatin solution is preferably 20-35%, and the gelatin is preferably added with pectin and sodium alginate. A soft capsule prepared by this process is free from characteristic ill odor of bifidus bacteria, has excellent palatability and has high survivability of the bifidus bacteria in the capsule. The bifidus bacteria useful as an intestine-conditioning agent reaches the intestine in living state.
Pharmaceutical compositions for the treatment of climacteric disorders comprise at least one physiologically compatible salt of oestrone sulphate and at least one physiologically compatible salt of the 3-sulphate of 1, 3, 5 (10)- oestratriene-3, 17#-diol, together with a solid and/or liquid pharmaceutical diluent or carrier. The salts may be alkali metal, alkaline earth metal, aluminium, iron, ammonium or substituted ammonium salts, preferably the sodium salts. The compositions may be administered parenterally as solutions, suspensions, or emulsions or enterally as tablets, dragees, syrups or juices. The composition may contain at least one additional active substance which may be selected from tranquillising substances, vitamins and steroids (e.g. oestrogens, androgens or gestragens such as chlormadinone acetate). Stabilizers, e.g. diethanolamine, N-methyl-glucosamine, sodium citrate, sorensen&#39;s buffer (a mixture of disodium hydrogen phosphate and potassium dihydrogen phosphate), and magnesium oxide may be present.
This invention is based on strong antioxidants which are useful for all age group. The basic composition of ingredients are-EPA 150 mg, DHA 100 mg, Folic Acid 5 mg and Lycopene 50 mg. DHA is a major fatty acid in sperm and brain phospholipids, particularly in the retina. Dietary DHA may reduce the risk of heart disease by reducing the level of blood triglycerides in humans. Low levels of DHA have been associated with Alzheimer&#39;s disease. Vitamin B9 (folic acid and folate inclusive) is essential to numerous bodily functions ranging from nucleotide biosynthesis to the remethylation of homocysteine. The human body needs folate to synthesize DNA, repair DNA, and methylate DNA as well as to act as a cofactor in biological reactions involving folate. It is especially important during periods of rapid cell division and growth. Both children and adults require folic acid to produce healthy red blood cells and prevent anemia. Folate and folic acid derive their names from the Latin word folium (which means &#34;leaf&#34;). Leafy vegetables are a principal source, although in Western diets fortified cereals and bread may be a larger dietary source. EPA has inhibitory effect on CYP2C9 and CYP2C19 hepatic enzymes. At high dose, it may also inhibit the activity of CYP2D6 and CYP3A4, important enzymes involved in drug metabolism. EPA improves the response of patients to chemotherapy, possibly by modulating the production of eicosanoid. It might also reduce the risk of developing certain types of cancer; including multiple myeloma. Lycopene helps neutralize harmful free radicals, which are implicated in cancer, heart disease, macular degeneration and other age- related illnesses. The evidence for a benefit was strongest for cancers of the prostate, lung, and stomach. Data were also suggestive of a benefit for cancers of the pancreas, colon and rectum, esophagus, oral cavity, breast, and cervix.
PURPOSE:To prevent the generation of precipitate in an aqueous system containing bivalent metal ion by using a peptide originated from vegetable protein and having specific average peptide chain length, phytic acid content and free amino acid content. CONSTITUTION:An enzyme (e.g. endo-type protease originated from microorganism of genus Aspergillus) is added to an aqueous solution of pH 6-8 produced by dissolving a vegetable protein in water. The decomposed solution produced by the enzymatic decomposition of the above protein solution is concentrated and dried to obtain a solution having a concentration of 5-35%. The solution is added with 0.4-1.6wt.% (in terms of bivalent metal) of a substance dissociable to bivalent metal ion (e.g. CaCl2) and heated at &gt;=70 deg.C. The generated precipitate is removed and the solution is as necessary concentrated and dried to obtain a peptide mixture having an average peptide chain length of 2-10, a phytic acid content of &lt;=1wt.% (in dried solid) and a free amino acid content of &lt;=20wt.%.
A home medical supervision and monitoring system with computer-controlled base station provides medical supervision of an individual and controls medical monitoring, environmental, and safety devices. Modular electronic components, a real-time operating system and multilevel application software provide decision-making choices to inform a monitoring service or the like if a medical crisis is occurring or an adverse environmental or safety condition exists. 
     Subsystems include medical monitoring devices to control and monitor specific medical conditions. If a crisis is detected, predefined physician instructions are implemented. A daily medical supervision subsystem records messages to be played back at preset intervals to supervise the individual&#39;s daily medical, safety or environmental activities under control of application software. A personal distress call subsystem can contact a monitoring service by pushing a distress button or by voice activating a communication circuit via a speaker telephone. Safety and environmental sensing devices such as motion, fire, smoke, etc., detect abnormal conditions and notify the base station while an archiving subsystem collects and processes information on a hard drive for later retrieval. The system has an optional medication-dispensing cabinet that will open a compartment at a prescribed time containing prescribed medication.
PURPOSE:To provide a new compound having DNA topoisomerase inhibitory activity, useful as an oncotherapeutic agent. CONSTITUTION:The objective compound of formula I [X and Y are each H, mercapto or lower alkylthio, being combined into (S)n (n is 1-4); Z is H or (substituted) carbamoyl] or a salt thereof, e.g. TAN-1496A of formula II. The compound of the formula I can be obtained from a product which is formed by culture of microorganisms belongning to Microspheropsis and halving ability to produce a compound of formula III (n&#39; is 2-4) (e.g. Microspheropsis sp. FL-16144 strain) in a liquid medium (pref. adjusted to pH 5 to 8) at 20-30 deg.C for 48-144hr.
1,200,438. Zeaxanthin. HOFFMANN-LA ROCHE &amp; CO. A.G. 13 March, 1969 [22 March, 1968], No. 13203/69. Heading C2C. Zeaxanthin is produced by allowing a hydride to act on dihydrorhodoxanthin in the presence of an inert solvent. The hydride may be a mixed metal hydride or an alkyl metal hydride- The dihydrorhodoxanthin may be prepared by reduction of rhodoxanthin with zinc or cadmium in an organic acid in the presence of an optionally halogenated aliphatic or aromatic hydrocarbon.